This consideration would be relevant to the potential of an MGAT2 inhibitor for the treatment of nonalcoholic steatohepatitis through improvement of whole‐body metabolism, such as weight loss 15. The gene discussed is MGAT2; the disease is metabolic dysfunction-associated steatohepatitis.